Evidence map›Paper›PMID 40716009›Full record

SynthesisInternational urology and nephrology2026

Efficacy and safety of complement inhibitors in IgAN: a systematic review and meta-analysis.

Boyu Mo, Jiamei Xu, Congyuan Ma, Xuanwei Li, Ping Zhu

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Boyu Mo *Institution of Nephrology, The First College of Clinical Medical Science, China Three Gorges University, Yichang, 443003, Hubei, China.
Jiamei Xu *Institution of Nephrology, The First College of Clinical Medical Science, China Three Gorges University, Yichang, 443003, Hubei, China.
Congyuan MaInstitution of Nephrology, The First College of Clinical Medical Science, China Three Gorges University, Yichang, 443003, Hubei, China.
Xuanwei LiInstitution of Nephrology, The First College of Clinical Medical Science, China Three Gorges University, Yichang, 443003, Hubei, China.
Ping ZhuInstitution of Nephrology, The First College of Clinical Medical Science, China Three Gorges University, Yichang, 443003, Hubei, China. topgan2000@163.com.

Funding

Hubei Provincial Department of Education Natural Science Research Project Fund,Yichang Medical and Health Research Project Fund B2017024,A20-2-002
6 · The paper itself

Abstract

purposeThe benefits and risks of complement inhibitors for the treatment of immunoglobulin A nephropathy (IgAN) remain uncertain. We conducted this systematic review and meta-analysis to compare the efficacy and safety of complement inhibitors vs. placebo.

methodsThe PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov databases were searched until December 20, 2024. This study analyzed the effects of complement inhibitors on the 24-h urinary protein-to-creatinine ratio (24-h UPCR), estimated glomerular filtration rate (eGFR), and the incidence of adverse events in IgAN.

resultsIn total, 4 studies with 398 patients were included in the systematic review and meta-analysis. In patients with IgAN, complement inhibitors significantly attenuated the decline in eGFR [MD = 3.50 ml/min/1.73 m

conclusionComplement inhibitors appear to confer renal protective effects without increasing the risk of adverse events in patients with IgAN.

Indexed as

Complement Inactivating AgentsGlomerulonephritis, IGAHumansTreatment OutcomeComplement Inactivating Agents24-h urinary protein-to-creatinine ratio (24-h UPCR)Complement inhibitorsEstimated glomerular filtration rate (eGFR)Immunoglobulin A nephropathy (IgAN)Meta-analysis

Identifiers

PMID40716009

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.